From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
This article was originally published in The Pink Sheet Daily
Executive Summary
3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.
You may also be interested in...
With Government Support, China Medical City Looks To Separate Itself From The Pack
NEW YORK - Perhaps the largest hurdle China Medical City faces with a U.S. audience is explaining how it differs from China's more established science and technology parks like Zhangjiang Hi Tech Park in Shanghai, Zhong-guan-cun Life Science Park in Beijing and BioBay in Suzhou
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
SHANGHAI - Last year was a banner year for China's life sciences companies, with 34 new stock offerings globally that raised $6.9 billion from the capital market. But the first half of 2011 has been a disappointment across healthcare sectors for Chinese firms
Is China A Black Swan For Big Pharma? (Part 2 of 2)
[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]